GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Paliperidone palmitate - INVEGA SUSTENNA monthly injection

Local official-label summaryBase record retrieved 2026-09-08See the evidence for this drug2 sources available - open source summaries, references and comparisons

INVEGA SUSTENNA / INVEGA SUSTENNA injection / paliperidone palmitate

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
SUSTENNA: the official renal subsection supplies additional maintenance detail

The retrieved RX renal subsection gives a usual maintenance dose but omits the adjustable range and maximum in the official label. An omission is not evidence of opposing dose recommendations.

Before applying: Use the complete product-specific source; do not extrapolate maintenance limits from the oral or longer-interval products.

Also check: SUSTENNA: the official renal subsection supplies additional maintenance detail

Official source

Paliperidone palmitate - INVEGA SUSTENNA monthly injection

Product / population
Adults; INVEGA SUSTENNA intramuscular monthly suspension. Not oral paliperidone or the longer-interval injections.
Renal measure
Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.

PI revision not established in this selected retrieval. Do not substitute a patient-information date for a prescribing-information revision.

Renal dosing, restrictions and evidence limits

At CrCl 50 to <80, initiate 156 mg on day 1 and 117 mg on day 8, both deltoid. The usual subsequent monthly dose is 78 mg, deltoid or gluteal. Depending on response and tolerability, renal maintenance choices are 39, 78, 117 or 156 mg; the maximum is 156 mg monthly. CrCl <50 is not recommended. Establish oral paliperidone or risperidone tolerability first when the patient has never received either.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-08. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1af14e42-951d-414d-8564-5d5fce138554

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Paliperidone palmitate - INVEGA SUSTENNA monthly injection

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adults; INVEGA SUSTENNA intramuscular monthly suspension. Not oral paliperidone or the longer-interval injections.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Retrieved: 2026-09-08

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - INVEGA SUSTENNA

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adults; INVEGA SUSTENNA intramuscular monthly suspension. Not oral paliperidone or the longer-interval injections.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Retrieved: 2026-09-08

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

source scope

SUSTENNA: the official renal subsection supplies additional maintenance detail

The retrieved RX renal subsection gives a usual maintenance dose but omits the adjustable range and maximum in the official label. An omission is not evidence of opposing dose recommendations.

How to use this: Use the complete product-specific source; do not extrapolate maintenance limits from the oral or longer-interval products.

GlobalRPh RX List - INVEGA SUSTENNAPaliperidone palmitate - INVEGA SUSTENNA monthly injectionPaliperidonePaliperidone palmitate - INVEGA TRINZA three-month injectionPaliperidone palmitate - INVEGA HAFYERA six-month injection

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopePaliperidone palmitate - INVEGA SUSTENNA monthly injectionGlobalRPh RX List - INVEGA SUSTENNA
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/invega-sustenna-drug/

Exact product and population

Adults; INVEGA SUSTENNA intramuscular monthly suspension. Not oral paliperidone or the longer-interval injections.

RDM44-SCOPE-paliperidone-invega-sustenna · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Paliperidone palmitate - INVEGA SUSTENNA monthly injection

Open original reference

Open / share this exact local source

DailyMed / Janssen Pharmaceuticals, Inc. · Adults; INVEGA SUSTENNA intramuscular monthly suspension. Not oral paliperidone or the longer-interval injections.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-08

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

At CrCl 50 to <80, initiate 156 mg on day 1 and 117 mg on day 8, both deltoid. The usual subsequent monthly dose is 78 mg, deltoid or gluteal. Depending on response and tolerability, renal maintenance choices are 39, 78, 117 or 156 mg; the maximum is 156 mg monthly. CrCl <50 is not recommended. Establish oral paliperidone or risperidone tolerability first when the patient has never received either.

RDM44-official-paliperidone-invega-sustenna-186d112b43-C1 · Source locator: Sections 2.2 and 2.5: initiation, tolerability and renal impairment; lines 215-218 and 474 onward.

Source-specific limits

PI revision not established in this selected retrieval. Do not substitute a patient-information date for a prescribing-information revision.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1af14e42-951d-414d-8564-5d5fce138554
Retrieved
2026-09-08
Exact label title
Paliperidone palmitate - INVEGA SUSTENNA monthly injection
DailyMed Set ID
1af14e42-951d-414d-8564-5d5fce138554
Labeler
Janssen Pharmaceuticals, Inc.
Renal-function method
Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
05e106ed62f882911f11014bb486753144a672c17aa03fc131e4377357cc6bbc
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - INVEGA SUSTENNA

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adults; INVEGA SUSTENNA intramuscular monthly suspension. Not oral paliperidone or the longer-interval injections.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-08

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For CrCl 50 to <80, the RX renal subsection starts 156 mg on day 1 and 117 mg one week later, both deltoid; monthly maintenance is 78 mg, deltoid or gluteal. Use is not recommended below CrCl 50. This retrieved subsection does not supply the adjustable maintenance range or renal maximum found in the separately stored official label.

RDM44-rxlist-paliperidone-invega-sustenna-723daf4bbb-C1 · Source locator: Dosage and Administration: Patients with renal impairment, lines 112-114.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/invega-sustenna-drug/
Retrieved
2026-09-08
Renal-function method
Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
7f5cb71a8597535094621e26c6c2bdc96434f3cc2afc0bf90e0543024e812df4

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/invega-sustenna-drug/
Source retrieval
2026-09-08. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
203f5f5ee73b50ae34394856a1128e707337933112196dd3011ec40c969b6e81
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report